A human microsatellite DNA-mimicking oligodeoxynucleotide with CCT repeats negatively regulates TLR7/9-mediated innate immune responses via selected TLR pathways

Clinical Immunology

Volumn 134, Issue 3, 2010, Pages 262-276

  Sun, Ran ^a,c   Sun, Luguo ^a   Bao, Musheng ^b   Zhang, Yongsheng ^a   Wang, Li ^a   Wu, Xiuli ^a   Hu, Dali ^a   Liu, Yongjun ^b   Yu, Yongli ^a   Wang, Liying ^a  

^a Basic Medical College   (China)

^b UNIVERSITY OF TEXAS   (United States)

^c JILIN UNIVERSITY   (China)

Author keywords

IFN ; MS ODN; pDC activation; TLR activation associated diseases; TLR7 9 selective inhibition

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; MICROSATELLITE DNA; OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOREGULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LIVER; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CERCOPITHECUS AETHIOPS; DENDRITIC CELLS; DNA VIRUS INFECTIONS; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; KAPLAN-MEIERS ESTIMATE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICROSATELLITE REPEATS; OLIGODEOXYRIBONUCLEOTIDES; RANDOM ALLOCATION; RNA VIRUS INFECTIONS; SPECIFIC PATHOGEN-FREE ORGANISMS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; VERO CELLS;

EID: 76049114916     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.11.009     Document Type: Article

References (37)

1. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4 (2004) 249-258
2. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1531
3. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
4. Hochrein H., Schlatter B., O'Keeffe M., Wagner C., Schmitz F., Schiemann M., Bauer S., Suter M., and Wagner H. Herpes simplex virus type-1 induces IFN production via Toll-like receptor 9-dependent and -independent pathways. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11416-11421
5. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6 (2006) 823-835
6. Ichikawa H.T., Williams L.P., and Segal B.M. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169 (2002) 2781-2787
7. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., and Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25 (2006) 417-428
8. Wang L., Jiang W., Ding G., Cao H., Lu Y., Luo P., Zhou H., and Zheng J. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-α release. Int. Immunopharmacol. 7 (2007) 646-655
9. Peter M., Bode K., Lipford G.B., Eberle F., Heeg K., and Dalpke A.H. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology 123 (2008) 118-128
10. Us D. Cytokine storm in avian influenza. Mikrobiyol. Bul. 42 (2008) 365-380
11. Krieg A.M., Wu T., Weeratna R., Efler S.M., Love-Homan L., Yang L., Yi A.K., Short D., and Davis H.L. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 12631-12636
12. Pisetsky D.S., and Reich C.F. Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clin. Immunol 96 (2000) 198-204
13. Shirota H., Gursel I., Gursel M., and Klinman D.M. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J. Immunol 174 (2005) 4579-4583
14. Zeuner R.A., Ishii K.J., Lizak M.J., Gursel I., Yamada H., Klinman D.M., and Verthelyi D. Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum. 46 (2002) 2219-2224
15. Dong L., Ito S., Ishii K.J., and Klinman D.M. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB-NZW mice. Arthritis Rheum. 52 (2005) 651-658
16. Barrat F.J., Meeker T., Chan J.H., Guiducci C., and Coffman R.L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37 (2007) 3582-3586
17. Hu D., Su X., Sun R., Yang G., Wang H., Ren J., Sun L., Wu X., Hu X., Yu Y., and Wang L. Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells. Mol. Immunol. 46 (2009) 1387-1396
18. Shiau M.Y., Chiou H.L., Lee Y.L., Kuo T.M., and Chang Y.H. Establishment of a consistent L929 bioassay system for TNF-alpha quantitation to evaluate the effect of lipopolysaccharide, phytomitogens and cytodifferentiation agents on cytotoxicity of TNF-alpha secreted by adherent human mononuclear cells. Mediators Inflamm. 10 (2001) 199-208
19. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23 (2005) 275-306
20. Maeda T., Murata K., Fukushima T., Sugahara K., Tsuruda K., Anami M., et al. A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int. J. Hematol. 81 2 (2005) 148-154
21. Yamada H., Gursel I., Takeshita F., Conover J., Ishii K.J., Gursel M., et al. Effect of suppressive DNA on CpG induced immune activation. J. Immunol. 169 (2002) 5590-5594
22. Lenert P., Stunz L., YI A.K., Krieg A.M., and Ashman R.F. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappa B activation. Antisense Nucleic Acid Drug. Dev. 11 (2001) 247-256
23. Gursel I., Gursel M., Yamada H., Ishii K.J., Takeshita F., and Klinman D.M. Repetitive elements in mammalian telomeres Suppress bacterial DNA-induced immune activation. J. Immunol. 171 (2003) 1393-1400
24. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., Chang B., Duramad O., and Coffman R.L. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202 (2005) 1131-1139
25. Stunz L.L., Lenert P., Peckham D., Yi A.K., Haxhinasto S., Chang M., Krieg A.M., and Ashman R.F. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur. J. Immunol. 32 (2002) 1212-1222
26. Haas T., Metzger J., Schmitz F., Heit A., Müller T., Latz E., and Wagner H. The DNA sugar backbone 2 deoxyribose determines Toll-like receptor 9 activation. Immunity 28 (2008) 315-323
27. Sparwasser T., Miethke T., Lipford G., Borschert K., Häcker H., Heeg K., and Wagner H. Bacterial DNA causes septic shock. Nature 386 (1997) 336-337
28. Nagaki M., and Moriwaki H. Implication of cytokines: roles of tumor necrosis factor-alpha in liver injury. Hepatol. Res. (2008) S19-S28 (The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan)
29. Geeraedts F., Goutagny N., Hornung V., Severa M., de Haan A., Pool J., Wilschut J., Fitzgerald K.A., and Huckriede A. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 4 (2008) e1000138
30. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus A. N. Abdel-Ghafar, T. Chotpitayasu-nondh, Z. Gao, F.G. Hayden, D.H. Nguyen, M.D. de Jong, A. Naghdaliyev, J.S. Peiris, N. Shindo, S. Soeroso, T.M. Uyeki, Update on avian influenza A (H5N1) virus infection in humans, N. Engl. J. Med. 358 (2008) 261-273.
31. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3 (2002) 196-200
32. Calcaterra C., Sfondrini L., Rossini A., Sommariva M., Rumio C., Ménard S., and Balsari A. Critical role of TLR9 in acute graft- versus-host disease. J. Immunol. 181 (2008) 6132-6139
33. Boulé M.W., Broughton C., Mackay F., Akira S., Marshak- Rothstein A., and Rifkin I.R. Toll-like receptor 9 dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199 (2004) 1631-1640
34. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., and Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115 (2005) 407-417
35. Baccala R., Hoebe K., Kono D.H., Beutler B., and Theofilopoulos A.N. TLR dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat. Med. 13 (2007) 543-551
36. Baenziger S., Heikenwalder M., Johansen P., Schlaepfer E., Hofer U., Miller R.C., Diemand S., Honda K., Kundig T.M., Aguzzi A., and Speck R.F. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 113 (2009) 377-388
37. Trieu A., Roberts T.L., Dunn J.A., Sweet M.J., and Stacey K.J. DNA motifs suppressing TLR9 responses. CRC Crit. Rev. Immunol. 26 (2006) 527-544